|
Market Closed -
Nasdaq
16:00:00 2026-08-25 EDT
|
5-day change | 1st Jan Change | ||
| 4.160 USD | +2.21% |
|
+2.21% | -26.63% |
| 08-06 | MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says | MT |
| 08-05 | MannKind Corporation, Q2 2026 Earnings Call, Aug 05, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MANNKIND CORPORATION | Bio Therapeutic Drugs | +2.21% | +2.21% | -26.63% | +6.67% | -9.57% | 1.34B |  |  | |
- Stock Market
- Stocks
- MNKD Stock
- Charts MannKind Corporation
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
